EGFR and colorectal carcinoma: In addition to Wnt/β-catenin, EGCG has shown to reduce the level of cyclooxygenase (COX)-2, one of the main mediators in the inflammatory signaling pathway, by inhibiting the activation of the epidermal growth factor receptor (EGFR) in CRC cells [60].